Clinical Trial Update: Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating hypofractionated stereotactic radiotherapy combined with anlotinib for recurrent high-grade gliomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Huashan Hospital | Conditions: Malignant Glioma | Phase 2 | Status: UNKNOWN